Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Sanofi

(RTTNews) - Sanofi has entered into an agreement to acquire Vicebio, a privately held biotechnology company headquartered in London, UK. Sanofi would acquire all of Vicebio's share capital for a total upfront payment of $1.15 billion, with potential milestone payments of up to $450 million based on development and regulatory achievements. Sanofi said the acquisition will not have a significant impact on financial guidance for 2025.
The company said the acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus and human metapneumovirus, and expands the capabilities in vaccine design and development with Vicebio's Molecular Clamp technology.
"Vicebio's 'Molecular Clamp' technology introduces a purposefully simple but thoughtful approach to further improve vaccine designs at a time when respiratory viral infections continue to impact millions globally", said Jean-François Toussaint, Global Head of Research and Development Vaccines at Sanofi.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi To Acquire Vicebio

Shares of Kymera KYMR have surged 70.7% in the past three months compared with the industry’s gain of 9.7%. The stock has also outperformed the sector and the S&P 500 index during this timeframe.
This clinical-stage biotechnology company is pioneering the field of targeted protein degradation (TPD) to develop drugs for various immunological diseases.
KYMR Outperforms Industry, Sector & S&P 500
Image Source: Zacks Investment Research
While the recent update in its deal with pharma giant Sanofi SNY caused a setback, investors are impressed with its recent collaboration with biotech giant Gilead Sciences, Inc. GILD.
KYMR’s License Deal With GILD Impresses Investors
Kymera recently entered into an exclusive option and license agreement with GILD to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the companies, CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
While traditional inhibitors of CDK2 prevent it from working but often interfere with similar proteins, leading to undesired side effects, MGDs have the potential to provide more precise, safe and effective treatments for cancers that rely on CDK2 activity by selectively removing this protein from cells.
Under the terms of the agreement, Kymera will receive an upfront payment of $85 million and potential option exercise payments. The total payments will range up to $750 million.
Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. While Kymera will lead all research activities for the CDK2 program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if it exercises its option to exclusively license the program.
KYMR’s Deal With Sanofi
Kymera had collaborated with Sanofi for the development of drug candidates targeting IRAK4, including KT-474/SAR444656, outside the oncology and immuno-oncology fields.
However, Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical studies.
The candidate was discovered by Kymera.
KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration following extensive preclinical work supporting its robust development potential. The candidate is expected to advance into early-stage testing next year.
Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.
Sanofi will not develop KT-474 any further. The company has also decided to exercise its participation election right for the IRAK4 target under the terms of the collaboration agreement. Per the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 (related to preclinical activities associated with KT-485).
Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the initiation of phase I clinical testing.
Our Take on Kymera’s Recent Performance
While the oncology deal with GILD looks promising and the subsequent influx of cash is positive, there is still a long way to go.
Sanofi's decision to advance preclinical IRAK4 degrader KT-485 rather than advancing KT-474 delayed milestone payments for Kymera that could have been achieved on the potential approval of KT-474, which had moved to phase IIb studies in late 2023.
Nonetheless, Kymera’s novel TPD approach is promising, and the pipeline progress is encouraging. In April, Kymera initiated dosing in the KT-621 BroADen phase Ib study in moderate to severe atopic dermatitis (AD) patients. Kymera plans to begin two parallel phase IIb studies in AD and asthma patients in the fourth quarter of 2025 and the first quarter of 2026, respectively.
Kymera named KT-579, an oral IRF5 degrader, as its lead development candidate and intends to advance the program into phase I testing in early 2026. IND-enabling studies are ongoing.
Kymera currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock has underperformed the medical sector and S&P 500 Index in this timeframe.
A decline in lead drug Eylea sales has adversely impacted top-line growth.
Regeneron Underperforms Industry, Sector and S&P 500
Image Source: Zacks Investment Research
While the company is making efforts to diversify its revenue base and develop its oncology franchise, Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ sentiment.
Pipeline setbacks have also hurt the share price of late.
Eylea’s Sales Decline Hampers REGN Ophthalmology Unit
Lead drug Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. Eylea sales have boosted the company’s top line for many years. However, Eylea’s sales have been under pressure in the past couple of years due to competition from Roche’s RHHBY Vabysmo.
The uptake of Roche’s Vabysmo has been phenomenal. Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A.
Biosimilar competition for Eylea is also worrisome. Since Eylea accounts for a majority of REGN’s sales, a rapid decline in sales has adversely impacted the company’s top line.
To counter the decline in Eylea sales, Regeneron has developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it will take Eylea HD quite some time to offset the rapid erosion in Eylea sales.
In April 2025, the FDA accepted for priority review a supplemental biologics license application (sBLA) seeking approval of Eylea HD for both the treatment of macular edema following retinal vein occlusion (RVO) and broadening the dosing schedule to include every 4-week (monthly) dosing across approved indications. The FDA has set a target action date of Aug. 19, 2025.
However, the regulatory body issued a complete response letter (“CRL”) for the pre-filled syringe of Eylea HD. Per the company, the key outstanding issue relates to a question posed by the FDA to a third-party component supplier. This component supplier has expeditiously responded to FDA requests for information.
The FDA also issued a CRL regarding the sBLA for the addition of extended dosing intervals. The FDA indicated that the submitted data did not support extended dosing intervals greater than every 16 weeks.
Regeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.
Dupixent Boosts REGN’s Top Line
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi SNY records global net product sales of Dupixent.
Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for Sanofi and Regeneron.
SNY and REGN are working to expand the drug’s label further. The FDA had earlier approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.
In April 2025, Dupixent’s label was further expanded for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment. The FDA recently approved Dupixent for the treatment of adult patients with bullous pemphigoid.
Strong demand trends and consistent label expansion should fuel Dupixent sales.
REGN’s Focus on Oncology
The company also has other arrows in its quiver. It is looking to strengthen its oncology franchise, which comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer.
REGN’s oncology franchise received a boost with the EC’s approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono.
However, the company’s efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its biologics license application (BLA) for odronextamab in March 2024.
The FDA accepted for review the resubmission of the BLA for odronextamab with a target action date of July 30, 2025.
Regeneron recently obtained FDA approval of linvoseltamab-gcpt for the treatment of R/R multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic.
Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
The successful development of these oncology drugs should be a great boost for REGN.
REGN Looking to Build an Obesity Franchise
Regeneron is looking to make inroads in the lucrative obesity market.
The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio.
The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist.
Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau.
The in-licensing agreement for an obesity candidate will expand REGN’s obesity pipeline, which includes trevogrumab.
The successful development of any obesity treatment will be a great boost for the company.
REGN: Valuation & Estimates
Going by the price/earnings ratio, REGN is expensive at this moment. Shares currently trade at 18.27X forward earnings, slightly lower than its mean of 18.85X but higher than the large-cap pharma industry’s value of 15.04X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has dropped 57 cents to $36.15 over the past 60 days and the same for 2026 has decreased $1.49.
Image Source: Zacks Investment Research
Final Thoughts on Regeneron
Large biotech companies are considered safe havens for investors interested in this sector.
However, Regeneron is sailing in troubled waters as of now and has a tough road ahead, as it will take a long time for Eylea HD to replace Eylea sales.
The stock got hammered at the end of May after REGN and partner Sanofi reported mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease.
While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same.
We believe that the near-term pipeline setbacks and challenges with Eylea weigh on the stock for now. We would advise prospective investors to be on the sidelines for the time being. For investors already owning the stock, selling it at current levels would be prudent.
REGN currently carries a Zacks Rank #4 (Sell).
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?

(RTTNews) - Thermo Fisher Scientific Inc. (TMO), Wednesday announced the decision to acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey. The financial terms of the deal were not disclosed.
The acquisition of the state-of-the-art sterile fill-finish and packaging facility is expected to strengthen Thermo Fisher's U.S. manufacturing capabilities, enabling it to better support its pharmaceutical and biotech customers.
Upon completion of the transaction, the facility will become part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.
The transaction is expected to be completed in the second half of 2025.
In the pre-market hours, TMO is trading at $418.11, up 0.07 percent on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Thermo Fisher Scientific Signs Deal To Buy Sanofi's Steriles Manufacturing Site In Ridgefield

(RTTNews) - Sanofi S.A. (SNYNF,SNY) said that the U.S. Food and Drug Administration has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration or AMD.
The fast track designation process aims to facilitate the development and expedite the review of medicines to treat serious conditions and fill unmet medical need. The FDA created this process to help deliver important new drugs to patients earlier and it covers a broad range of serious illnesses.
Sanofi said it plans to start a phase 1/2 study to evaluate the safety, tolerability, and efficacy of SAR446597.
Sanofi is also currently evaluating SAR402663, a one-time intravitreal gene therapy, in a phase 1/2 study, for the treatment of patients with neovascular wet age-related macular degeneration.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi's SAR446597 Granted FDA Fast Track For Gene Therapy Tackling Vision Loss In AMD

Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and broaden its product portfolio. To build its long-term portfolio, the company has invested heavily in strategic mergers and acquisitions (M&A) activity during the past couple of years.
Last week, Merck announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. With this deal, Merck will add Verona’s Ohtuvayre, approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ohtuvayre was approved by the FDA in June last year, while regulatory filings in the EU are expected soon.
The addition of Ohtuvayre is likely to strengthen Merck’s cardio-pulmonary pipeline and portfolio as the drug’s differentiated profile provides a significant edge over its competitors. The drug’s unique dual inhibition of PDE3 and PDE4 sets it apart from existing COPD treatments by combining bronchodilation and anti-inflammatory effects in a single inhaled therapy.
The transaction is expected to be closed in the fourth quarter of 2025. Once closed, Verona Pharma would mark Merck’s largest acquisition since its $10.8 billion takeover of immunology-focused Prometheus Bioscience in 2023.
Merck has been tapping Chinese biotechs for licensing deals in recent times. The company struck multi-billion-dollar deals with Hansoh Pharma, LaNova Medicines and Hengrui Pharma in late 2024. While the Hansoh deal added the investigational oral GLP-1 receptor agonist HS-10535 to Merck’s pipeline, the LaNova deal added the experimental bispecific VEGF/PD-1 antibody LM-299. With the Hengrui Pharma deal, Merck acquired rights to an investigational oral small-molecule lipoprotein(a) inhibitor, HRS-5346.
Importantly, these acquisition deals are aimed at Merck's continuous effort to diversify its business and grow its revenue base, which currently remains heavily dependent on its blockbuster PD-L1 inhibitor Keytruda. The company is looking for ways to diversify its product lineup, especially by growing its non-oncology business to navigate the potential challenges with the upcoming patent loss of Keytruda. Though Keytruda will lose patent exclusivity in 2028, its sales are expected to remain strong until then.
Big Pharma Players Set Sights on M&A Deals
M&A activity has picked up at a significant pace in 2025 in the pharma/biotech sector. Big pharma companies are constantly looking to diversify their revenue base while pursuing strategic assets in key growth areas.
Last month,Sanofi SNY announced a definitive agreement to acquire Blueprint Medicines for a total deal value of up to $9.5 billion. Through this transaction, Sanofi is looking to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis. Sanofi expects to close this deal in the third quarter of 2025.
Eli Lilly LLY also recently announced its intent to acquire small biotech Verve Therapeutics for up to $1.3 billion. Post this acquisition, Lilly will add Verve’s pipeline of gene therapies targeting heart diseases. Lilly expects to close this deal in the third quarter of 2025.
AbbVie recently signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value of nearly $2.1 billion. The transaction will add Capstan’s lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to AbbVie’s immunology pipeline.
MRK's Price Performance, Valuation and Estimates
Year to date, shares of Merck have lost 16.2% against the industry’s increase of 0.3%.
Image Source: Zacks Investment Research
From a valuation standpoint, Merck appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 8.98 forward earnings, lower than 15.13 for the industry and its 5-year mean of 12.82.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has declined from $8.94 per share to $8.85, while the same for 2026 has decreased from $9.77 to $9.66 over the past 60 days.
Image Source: Zacks Investment Research
Merck currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?

(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway for people with chronic inflammatory demyelinating polyneuropathy or CIDP.
Despite current therapies, many patients with CIDP continue to experience residual symptoms—such as weakness, numbness, and fatigue—that contribute to long-term morbidity and reduced quality of life. Notably, approximately 30% of patients do not respond to standard treatment, Sanofi said.
The company noted that the decision by Japan's Ministry of Health, Labour and Welfare joins similar designations in the US and Europe, highlighting global regulatory recognition of riliprubart's potential to address critical unmet needs in treating this rare neurological condition.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi's Riliprubart Receives Orphan Drug Status In Japan For Rare Nerve Disorder

Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474.
This setback was somewhat offset by KYMR’s announcement of an exclusive option and license agreement with biotech giant Gilead Sciences, Inc. GILD.
Kymera also commenced an underwritten public offering worth $250.0 million of its common stock.
The stock was down 1.4% on June 25 and dropped 6.91% in after-market trading, probably due to the setback in Sanofi’s partnership and dilution of equity.
Year to date, shares of KYMR have gained 15.5% against the industry’s decline of 2%.
Image Source: Zacks Investment Research
KYMR’s Update on Collaboration With Sanofi
Sanofi informed Kymera that it has selected KT-485/SAR447971, an oral, highly potent and selective development candidate targeting IRAK4 for immuno-inflammatory diseases, to advance into clinical studies.
The candidate was discovered by Kymera.
KT-485 is being prioritized for development under the companies’ existing IRAK4 collaboration following extensive preclinical work supporting its robust development potential. The candidate is expected to advance into early-stage testing next year.
Consequently, Sanofi has decided to let go of KT-474, which was being evaluated for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD) in two phase IIb dose-ranging studies.
Sanofi will not develop KT-474 any further. The company has also decided to exercise its participation election right for the IRAK4 target under the terms of the collaboration agreement. Per the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 (related to preclinical activities associated with KT-485).
Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the initiation of phase I clinical testing.
Kymera Therapeutics, Inc. Price, Consensus and EPS Surprise
More on KYMR’s License Deal With GILD
Kymera entered into an exclusive option and license agreement with Gilead to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, in breast cancer and other solid tumors.
Per the companies, CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor in tumor growth, rather than just inhibiting its function.
Under the terms of the agreement, Kymera will receive an upfront payment of $85 million and potential option exercise payments. The total payments will range up to $750 million.
Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. While Kymera will lead all research activities for the CDK2 program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration if the latter exercises its option to exclusively license the program.
KYMR Issues Shares
Concurrent with these business updates, Kymera announced the commencement of an underwritten public offering of $250.0 million of shares of its common stock.
Kymera intends to use the net proceeds from the offering to continue advancing its pipeline of preclinical and clinical degrader programs, which are designed to address large patient populations with significant needs and clear commercial opportunities. The proceeds will also be used for working capital and other general corporate purposes.
Our Take
While the oncology deal with GILD looks promising and the subsequent influx of cash is positive, investors were disappointed with the update from Sanofi.
Sanofi has decided to advance preclinical IRAK4 degrader KT-485 rather than advancing KT-474, which had moved to phase IIb studies in late 2023.
The move definitely delays milestone payments for Kymera that could have been achieved on the potential approval of KT-474.
Kymera currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

(RTTNews) - The U.S. Food and Drug Administration has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation, Sanofi Winthrop Industrie said in a statement.
Riliprubart has also been designated an orphan drug for its investigational use in treating chronic inflammatory demyelinating polyneuropathy in the US and European Union.
Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi's Riliprubart Secures U.S. Orphan Drug Status For Solid Organ Transplant Rejection

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the 200-day moving average of $50.71.
When a stock's price is below its 200-day moving average, it can be interpreted as a potential sign of weakness or a bearish trend in the stock. With Sanofi’s stock price going below its 50-day and 200-day moving averages, investors holding the stock are confused about whether they should consider selling the stock.
Let’s understand the company’s strengths and weaknesses to better analyze how to play Sanofi stock amid this scenario.
Dupixent: A Key Top-Line Driver for SNY
Sanofi and Regeneron’s REGN immunology drug, Dupixent, has become the key top-line driver as it enjoys strong demand across all approved indications and geographies. Dupixent is now approved in several countries, including the United States and the EU, for six type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma, moderate-to-severe atopic dermatitis, eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease (COPD). Sanofi/Regeneron’s Dupixent was approved for its seventh indication, chronic spontaneous urticaria, in the United States in April 2025 and for its eighth indication, bullous pemphigoid, in June.
Dupixent’s strong sales growth is being driven by demand across all geographies, newly approved indications and demographics. New uses, increased penetration in approved indications and further geographic expansion are expected to drive Dupixent’s sales in future quarters. Sanofi expects Dupixent to achieve around €22 billion in sales in 2030.
SNY Boasts a Strong Vaccine Segment
Sanofi possesses one of the world’s leading vaccine operations, with total annual sales of more than €5 billion in the past five years. Its Vaccines unit has delivered mid-to-high-single-digit sales growth since 2018. In 2024, Sanofi’s Vaccines segment recorded sales growth of 13.5% at CER, exceeding expectations of growing at a high single-digit range due to the successful rollout of Beyfortus, which reached €1.7 billion in sales. In the first quarter of 2025, total vaccine sales increased 11.4%. Sanofi continues to expand its vaccine business further. Some vaccine candidates that are in phase III development include a 21-valent pneumococcal conjugate vaccine and a next-generation rabies vaccine. Sanofi expects annual net sales to be more than €10 billion from its Vaccines unit by 2030, backed by its innovation efforts.
SNY’s New Products & Strong Pipeline Can Drive Long-Term Growth
Sanofi’s new products, like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy, Nexviazyme, and chronic graft-versus-host disease drug, Rezurock, are contributing to top-line growth. Revenues from these products are offsetting the impact of generic competition on Aubagio's sales.
Sanofi is investing in these launches to optimize their success. Beyfortus achieved blockbuster sales in its first full year of sales in 2024. Altuviiio is expected to achieve blockbuster sales in 2025.
Sanofi has a strong immunology and neuro-inflammation pipeline, which includes 12 potential blockbuster assets in phase III development, including amlitelimab, frexalimab and tolebrutinib.
A key new product, Qfitlia (fitusiran), was approved by the FDA in March 2025 to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B. FDA decisions on tolebrutinib for non-relapsing secondary progressive multiple sclerosis and rilzabrutinib for immune thrombocytopenia are expected this year.
SNY’s Several Headwinds
Generic versions of the key drug, Aubagio, were launched in the United States in March 2023 and in Europe at the end of September 2023, which significantly eroded the drug’s sales in 2023 and 2024. Aubagio sales are expected to continue to decline in 2025.
Sales of Sanofi’s influenza vaccines, which represented 30.8% of vaccines net sales, declined 1.4% in 2024 due to rising competitive and pricing pressure. The challenges are expected to continue. In the first quarter of 2025, influenza vaccine sales declined 1.4%. Sanofi believes that the influenza market is likely to have several new competitive entrants, both from standalone flu mRNA and COVID-flu combinations. In addition, intense pricing pressure and lower vaccine coverage can hurt sales of influenza vaccines in future quarters.
Competition for Beyfortus, which represented 20.3% of vaccine sales in 2024, may increase with the launch of Merck’s MRK new monoclonal antibody for RSV, Enflonsia, which was approved by the FDA earlier this month.
SNY’s Price, Valuation & Estimate Movement
Sanofi’s stock has risen 3.1% year to date against a decrease of 1.2% for the industry. The stock has also outperformed the sector and the S&P 500, as seen in the chart below.
SNY Stock Outperforms Industry, Sector and S&P 500
Image Source: Zacks Investment Research
From a valuation standpoint, Sanofi appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 10.15 forward earnings, lower than 14.81 for the industry. The stock also trades lower than its 5-year mean of 11.68. The stock is also much cheaper than other large drugmakers like Novo Nordisk, AstraZeneca, J&J, AbbVie and Lilly.
SNY Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has risen from $4.43 per share to $4.56 per share over the past 60 days. For 2026, earnings estimates have risen from $4.86 per share to $4.94 per share over the same timeframe.
SNY Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in SNY Stock
Sanofi faces its share of headwinds, like generic erosion of key drug Aubagio in all key markets and lower sales from mature products, which are hurting sales. Other headwinds include weak sales of influenza vaccines and regular negative pipeline developments.
However, Sanofi has increased R&D investments and is achieving significant progress with its pipeline. It has also been active on the M&A front. In less than two months, it announced proposed acquisitions of Blueprint Medicines and Vigil Neuroscience. While the BPMC deal will expand Sanofi’s presence in rare immunological diseases, the VIGL deal will boost Sanofi’s neurology pipeline.
In 2025, Sanofi expects sales to rise by a mid-to-high single-digit percentage at CER. Earnings are expected to rebound strongly, with an expectation of a low double-digit percentage growth at CER (before stock buyback) in 2025 versus 4.1% in 2024.
Sanofi’s price appreciation, rising estimates, reasonable valuation, improving top-line performance, potential contributions from new product launches and positive pipeline progress are good enough reasons for those who own this Zacks Rank #3 (Hold) stock to stay invested despite the stock's price going below its 50 and 200-day moving averages.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sanofi

Fundamental analysis

Ratios

Valuation

Debts

Efficiency

Other ratios

Revenue

Financials

Growth

Assets

Debts